Options for optimizing treatment of gastroesophageal reflux disease with proton pump inhibitors
https://doi.org/10.21518/2079-701X-2015-17-85-87
Abstract
Proton pump inhibitors (PPI) were successfully used for the treatment of acid-base disorders, in particular GERD, for the past 20 years. However, approximately 30% of patients with gastroesophageal reflux disease (GERD) do not adequately respond to standard PPI therapy due to the impact of many factors: patient-specific PPI metabolism in the liver, concomitant pathology of the digestive system, pharmacokinetic properties of traditional dosage forms of PPI. Persistence of GERD symptoms is particularly explained by the fact that the use of conventional single release PPI does not allow to fully control the cyrcadian rhythm of gastric secretion and should be taken twice a day before a meal, which has a negative effect on adherence. Thanks to dual delayed-release and longer presence in blood, dexlansoprazole MR showed high efficacy in the treatment and maintaining remission of various forms of GERD, as well as greater adherence to treatment.
About the Authors
M. F. Osipenko
Novosibirsk State Medical University
Russian Federation
Russian Federation
E. A. Bikbulatova
Novosibirsk State Medical University
Russian Federation
Russian Federation
S. I. Kholin
Novosibirsk State Medical University
Russian Federation
Russian Federation
References
1. Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther., 2006, 23(2): 2-8.
2. Sachs G, Shin J, Vagin O, Lambrecht N, Yakubov I, Munson K. The Gastric H, K ATPase of a Drug Target: past, present, and future. J Clin Gastroenterol, 2007, 41(2): 226-42.
3. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management-the Geneva Workshop report. Gut, 1999, 44(2): 1-16.
4. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesopha-geal reflux disease. Am J Gastroenterol, 2005, 100: 190-200.
5. Chey WD, Inadomi JM, Booher AM, Sharma VK, Fendrick AM, Howden CW. Primary- care physicians' perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol, 2005, 100: 1237-42.
6. Tonini M, DeGiorgio R, DePonti F. Novel therapeutic strategies in acid-related disorders. Expert Opin Ther Patents, 2003, 13: 639-49.
7. Ливзан М.А., Лялюкова Е.А. Гастроэзофагеальная рефлюксная болезнь, рефрактерная к терапии ингибиторами протонной помпы. Клинические наблюдения. Лечащий врач, 2015, 8: 18.
8. Hunt RH. Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005. Aliment Pharmacol Ther., 2005, 22(3): 10-9. 1949-56.
9. Ливзан М.А., Кононов А.В. Клинические и фармакоэкономические аспекты антисекреторной терапии гастроэзофагеальной рефлюксной болезни. Экспериментальная и клиническая, 2004, 4: 55-61.
10. Bate CM, Booth SN, Crowe JP, HepworthJones B, Taylor MD, Richardson PD. Does 40 mg omepra-zole daily offer additional benefit over 20 mg daily in patients requiring more than 4 weeks of treatment for symptomatic reflux oesophagitis? Aliment Pharmacol Ther, 1993, 7: 501-7.
11. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther, 2001, 23: 1296-310.
12. Бордин Д.С. Как выбирать ингибитор протонной помпы больному ГЭРБ? Экспериментальная и клиническая гастроэнтерология, 2010, 2: 53-58.
13. Miner P, Katz P, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol, 2003; 98: 2616-20. Scarpignato C, Pelosini I, Di Mario F.Acid suppression therapy: where do we go from here? Dig Dis., 2006; 24: 11-46.
14. Chey WD, Inadomi JM, Booher AM, Sharma VK, Fendrick AM, Howden CW. Primary- care physicians' perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol, 2005; 100: 1237-42.
15. Persson K. When do ulcer patients take their acid inhibiting medication? Hassle Information, 1993; 7: 19-23.
16. Nexium (esomeprazole magnesium). Full Prescribing Information. Wilmington, DE: AstraZeneca LP, 2008.
17. Sostek MB, Chen Y, Andersson T. Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole. Br J Clin Pharmacol, 2007; 64: 386-90.
18. Vaz-da-Silva M, Loureiro AI, Nunes T, et al. Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions. Clin Drug Investig, 2005; 25: 391-9.
19. Bergstrand R, Grind M, Nyberg G, Olafsson B. Decreased oral bioavailability of lansoprazole in healthy volunteers when given with a standard breakfast. Clin Drug Invest, 1995; 9: 67-71.
20. Behm BW, Peura DA. Dexlansoprazole MR for the management of gastroesophageal reflux disease. Expert Rev Gastroenterol Hepatol, 2011; 5: 439-445.
21. Kukulka M, et al. Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg. Clin Exp Gastroenterol, 2011; 4: 213-20.
22. Zhang W, et al. Pharmacokinetic, pharmacodynamic, and safety evaluation of single and multiple 60 mg, 90 mg, and 120 mg oral doses of modified release TAK-390 (TAK-390MR) and 30 mg oral doses of lansoprazole in healthy subjects. Gastroenterology, 2007; 132(4 Suppl 2) A487).
23. Vakily M et al. Pharmacokinetics and pharma-codynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansopra-zole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin, 2009; 25: 627-38.
24. Lee R, Vakily M, Mulford D, Wu J, Atkinson S. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor - evidence for dosing flexibility. Aliment Pharmacol Ther, 2009, 29: 824-833.
25. Lee R, Mulford D, Wu J, Atkinson S. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor. Aliment Pharmacol Ther, 2010; 31: 1001-1011.
26. Fass R, et al. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther, 2009; 29: 1261-72.
27. Nocon M, Labenz J, Jaspersen D, et al. Long-term treatment of patients with gastro-oesophageal reflux disease in routine care -results from the ProGERD study. Aliment Pharmacol Ther, 2007; 25: 715-22.
28. Metz DC, Howden CW, Perez MC, Larsen L, O'Neil J, Atkinson S.N. Clinical trial: dexlanso-prazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther., 2009; 29: 742-754.
29. Howden CW, et al. Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief. Aliment Pharmacol Ther, 2009; 30: 895-90.
30. Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol, 2004; 2: 656-64.
31. Fass R, Chey W, Zakko S, Andhivarothai N, Palmer R, Perez M., Atkinson S. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther, 2009; 29: 1261-1272.
32. Mody R, Bolge SC, Kannan H et al. Eff ects of gastroesophageal refl ux disease on sleep and outcomes. Clin Gastroenterol Hepatol, 2009; 7: 953-9.
33. Vakily M, Lee RD, Wu J, Gunawardhana L, Mulford D. Drag interaction studies with dex-lansoprazoli.modified relase (TAK-390MR), proton pomp imhibitor with a dual delayed-relase formulation; results of four randomized double-blind, crossover, single - centre studies. Clin Drag Investig. 2009; 29: 35-50.
Review
For citations:
Osipenko MF, Bikbulatova EA, Kholin SI. Options for optimizing treatment of gastroesophageal reflux disease with proton pump inhibitors. Meditsinskiy sovet = Medical Council. 2015;(17):85-87. (In Russ.) https://doi.org/10.21518/2079-701X-2015-17-85-87
Views:
402
Email this article 